Author
Started career assisting in the plastic surgery field before shifting to full-time aesthetic medicine. With over a decade of experience teaching different cosmetic and skincare procedures, David provides a keen awareness of emerging trends and technologies in the aesthetic field, guiding readers and trainees in maintaining a competitive edge.
Compare CJC-1295 vs Ipamorelin for GH research, including GHRH vs GHS-R1a signaling, pulsatile vs sustained release, and combination rationale.
Compare Tirzepatide vs Semaglutide insulin secretion mechanisms, including GLP-1R selectivity, GIPR co-activation, SURPASS-2 beta-cell data, and clamp findings for research.
Compare AOD-9604 vs Semaglutide across direct adipocyte lipolysis and GLP-1R appetite signaling, IGF-1 impact, and study-design fit for fat loss pathway research.
What is a defensible Botox price? Med Supply Solutions explains how sourcing, storage, vial handling, and unit costs shape the patient fee.
Compare AOD-9604 vs Tesamorelin in fat-reduction research: direct adipocyte lipolysis, GHRH-driven GH release, IGF-1 signaling, and visceral fat data.
Compare Ipamorelin vs GHRP-6 in preclinical research: GHS-R1a selectivity, cortisol and appetite differences, and pulsatile GH pulse amplitude data.
A research-focused comparison of Retatrutide vs Mazdutide, contrasting triple- and dual-receptor architecture, hepatic vs systemic endpoints, and current Phase 2/3 evidence.
Semaglutide vs Tirzepatide research: compare GLP-1 vs dual GLP-1/GIP receptor agonism, SURMOUNT and SUSTAIN outcomes, and protocol design considerations.
Tirzepatide vs Retatrutide in obesity and metabolic research: how triple GLP-1/GIP/glucagon receptor agonism differs from dual incretin activation.
Compare CJC-1295 vs Tesamorelin as GHRH analogues in visceral fat and metabolic research, with phase III VAT data, IGF-1 kinetics, and protocol notes.
Subscribe for exclusive offers and updates on new arrivals